Phase 4 Colorectal Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have fully understood the study and have signed a consent form agreeing to take part
• People aged 18 or older, of any gender
• People who have been diagnosed with advanced or metastatic colorectal cancer (a type of bowel cancer that has spread), confirmed by a tissue sample test
• People whose cancer got worse during, or who could not tolerate, at least one prior standard treatment containing the chemotherapy drugs fluorouracil, oxaliplatin, and irinotecan
• People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines
• People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activities)
• People with an expected survival of at least 12 weeks
• People whose blood counts and organ function results meet specific minimum levels in the 14 days before joining (covering blood cell counts, liver function, kidney function, and related measures — confirm details with the trial site)
• People who are willing and able to use effective contraception, if they are a woman of childbearing age or a man whose partner wishes to become pregnant

Who may not be able to join:

• People who have previously been treated with Fruquintinib, or similar drugs that target blood vessel growth (such as Apatinib, Regorafenib, or Anlotinib)
• People who have previously been treated with the chemotherapy drug Raltitrexed
• People who have taken part in another drug clinical trial and received at least one dose within the four weeks before joining, or who have received any other cancer treatment (such as chemotherapy, immunotherapy, or hormone therapy) within the four weeks before joining
• People who have a condition that affects how the body absorbs medication, or who are unable to swallow Fruquintinib tablets
• People who currently have certain stomach or bowel conditions, such as active ulcers, ulcerative colitis, active bleeding from a tumour, or other conditions that may raise the risk of bleeding or a hole forming in the gut
• People who have active bleeding or a tendency to bleed
• People with a serious history of heart or brain blood vessel disease, including stroke (with some exceptions), heart attack, unstable chest pain, or poorly controlled heart rhythm problems within the six months before joining — or people with poor heart function based on standard medical ratings
• People who have had another type of cancer within the past five years (with the exception of certain fully treated skin cancers or cervical pre-cancer)
• People with clinically uncontrolled active infections, such as active pneumonia, or active hepatitis B or C at levels above specified limits
• People with brain metastases that are causing symptoms, or people with cancer that has spread to the lining around the brain (cancerous meningitis) — people with previously treated, stable brain metastases may be considered if specific conditions are met (confirm with the trial site)
• People who are pregnant or breastfeeding
• People with high blood pressure that cannot be controlled with medication, defined as blood pressure remaining at or above 140/90 mmHg while taking blood pressure medication
• People whose urine or 24-hour urine protein tests show levels above specified limits
• People considered unsuitable for the trial by the investigating doctors, for any other reason

Important: Always verify eligibility with the trial site directly before applying.